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Abstract
 
The induction of antigen-specific tolerance in the mature immune system of the intact organism
has met with limited success. Therefore, nonspecific immunosuppression has been the treatment
of choice to prevent unwanted immunity. Here, it is shown that prolonged subcutaneous
infusion of low doses of peptide by means of osmotic pumps transforms mature T cells into
CD4
 
 
 
25
 
 
 
 suppressor cells that can persist for long periods of time in the absence of anti-
gen and confer specific immunologic tolerance upon challenge with antigen. The described
procedure resembles approaches of tolerance induction used decades ago, induces tolerance in
the absence of immunity, and holds the promise to become an effective means of inducing
antigen-specific tolerance prospectively, whereas its power to suppress already ongoing immune
responses remains to be determined.
Key words: regulatory T cells • Ag-speciﬁc tolerance • in vivo induction • subcutaneous 
infusion • immunity
 
Introduction
 
Phenotypically distinct subsets of suppressor (regulatory) T
cells have been described previously (1–8). Of particular
interest are so-called “natural” CD4
 
 
 
25
 
 
 
 suppressor T cells
that are present among thymocytes and peripheral T cells
and that were shown to have an essential role in the pre-
vention of autoimmunity (9). Such cells express the 
 
Foxp3
 
gene at relatively high levels (10–13). Mutations of the 
 
Foxp3
 
gene in both mice and man are associated with severe
immunopathology (14–17). Experiments designed to eluci-
date the origin of CD4
 
 
 
25
 
 
 
 suppressor T cells in 
 
  
 
TCR
transgenic mice have revealed that such cells can be formed
intrathymically when the relevant agonist ligand for the
 
  
 
TCR is expressed on radioresistant tissue of the thymus
(2, 18, 19). Furthermore, in vivo analysis has shown that
CD4
 
 
 
25
 
 
 
 suppressor T cells represent a lineage of cells that
have a long intermitotic lifespan in the absence of Ag but
are nevertheless committed to suppressive function upon
challenge with Ag. In vivo CD4
 
 
 
25
 
 
 
 suppressive T cells are
capable of extensive Ag-induced proliferation during which
they up-regulate CD25 and develop increased suppressive
activity by inhibiting the proliferation and cytokine produc-
tion of other antigenically stimulated T cells (20–23). The
question whether natural suppressor cells can be generated
from naive T cells has been addressed in different ways.
Chronic confrontation of naive T cells with Ag has resulted
predominantly in the generation of anergic T cells that are
CD25
 
 
 
 and do not express 
 
Foxp3
 
 (24), whereas, in some
experiments, a small proportion of anergic and suppressive
CD4
 
 
 
25
 
 
 
 cells was also noted (2). In other experiments,
there was an apparent generation of CD25
 
 
 
 regulatory T
cells from CD25
 
 
 
 precursors when Ag was administered
either i.v. or orally, even though selective survival of some
preformed suppressor cells could not be entirely excluded
and 
 
Foxp3
 
 expression could not be analyzed (25). In a more
recent paper, it was shown that anti-CD3 stimulation in the
presence of TGF
 
 
 
 in vitro can result in the polyclonal stim-
ulation of CD25
 
 
 
 
 
Foxp3
 
-expressing suppressor T cells (26).
It was our interest to develop a protocol suitable to generate
CD25
 
 
 
 
 
Foxp3
 
-expressing regulatory T cells with defined Ag
specificity in vivo with the goal of generating Ag-specific
tolerance in the absence of concomitant immunity in the
fully mature immune system. Here, it is reported that
CD4
 
 
 
25
 
 
 
 T cells with the characteristics of natural suppressor
cells cannot only be generated intrathymically but can be
derived de novo from naive T cells after prolonged s.c.
infusion of their agonist peptide ligand in the absence of
proliferation of peptide-specific T cells. The peripherally
generated suppressor cells were indistinguishable in cell surface
phenotype, lifespan, and functional aspects from intra-
thymically generated 
 
Foxp3
 
 
 
CD4
 
 
 
25
 
 
 
 cells and were capable
of mediating tolerance in various in vivo readout systems.
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Materials and Methods
 
Animals and Peptide Delivery Pump Treatment. 
 
BALB/c
TCR-HA,RAG-2
 
 
 
/
 
 
 
 mice, Thy1.1 BALB/c congenic TCR-
HA,RAG-2
 
 
 
/
 
 
 
 mice, TCR-HA,Ig-HA mice, BALB/c mice,
and BALB/c nude mice used in this work were described previ-
ously (2). TCR-HA,Ig-HA mice and rat insulin promoter 
 
(
 
INS-
HA) transgenic BALB/c nude mice were bred in our animal fa-
cility. Unmanipulated 7–8-wk-old BALB/c mice or 7–8-wk-old
BALB/c TCR-HA,RAG-2
 
 
 
/
 
 
 
 mice that had been previously
thymectomized (Tx) were implanted s.c. with mini-osmotic
pumps (ALZET1002; Durect Corporation) diffusing PBS or the
indicated amount of influenza HA (107-119) peptide per day for
14 d. Animal care and all procedures were in accordance with the
guidelines of the Animal Care and Use Committee of the Dana-
Farber Cancer Institute.
 
Cell Preparations, Flow Cytometry, In Vitro Proliferation Assays,
Adoptive Transfer Experiments, 5-Bromodeoxyuridine (BrdU) Incorpo-
ration Assay, and Immunization. 
 
Cell preparations, flow cytom-
etry procedures, proliferation assays, and 5,6-carboxyfluorescein
diacetate-succinimidyl ester (CFSE) labeling of TCR-HA cells
before their transfer were performed as described previously (2,
20). BrdU incorporation assays were performed as follows. Two
osmotic pumps (ALZET2001; Durect Corporation) infusing 1.2
mg BrdU per day for 7 d were implanted s.c. at 7-d intervals.
BrdU detection in triple-stained cells was done with a fluorescein
isothiocyanate–conjugated anti-BrdU antibody (BD Biosciences)
according to the BD Biosciences BrdU flow kit instruction man-
ual. In transfer experiments, 2 
 
 
 
 10
 
5
 
 CFSE-labeled T cells and
3 
 
 
 
 10
 
5
 
 HA peptide-pulsed splenic DCs, prepared as described
previously (2), were coinjected intrasplenically into BALB/c
mice, and cell division of splenic CFSE-labeled T cells was exam-
ined by flow cytometry 4.5 d after transfer. DC immunization of
Tx and peptide-infused TCR-HA,RAG-2
 
 
 
/
 
 
 
 mice was con-
ducted by injecting 5.7 
 
 
 
 10
 
5
 
 HA peptide-pulsed DCs intra-
splenically. Splenic TCR-HA–expressing cells of such immunized
recipients were examined for intracellular cytokine production
after 4.5 d. INS-HA transgenic BALB/c nude mice were injected
with the indicated T cell subset into the lateral tail vein, and their
blood glucose levels were measured in 2–3-d intervals. Peptide-
infused (10 
 
 
 
g/d of HA peptide) or noninfused BALB/c mice
were immunized into each footpad with 1 
 
 
 
g of HA protein
(Protein Science Corporation) in IFA. 13 d after immunization,
poplitae (draining) as well as mesenteric LN cells from either the
aforementioned mice or unmanipulated control mice were col-
lected and cultured at 3–5 
 
 
 
 10
 
6
 
 cells/well in triplicate in vitro
for 2.5 d without any stimulus, with 0.05 
 
 
 
g/ml of HA protein,
or with 10 
 
 
 
g/ml of HA peptide. [
 
3
 
H]Thymidine at 1 
 
 
 
Ci/well
was added the last 16 h of the culture.
 
Real-Time RT-PCR. 
 
cDNAs from flow cytometry–sorted
cells were generated as described previously (2). Expression of
 
Foxp3
 
 and 
 
 
 
-actin
 
 was quantified by real-time PCR in a sequence
detection system (ABI Prism 7700; Applied Biosystems) using the
TaqMan
 
®
 
 1000 RXN gold with Buffer A Pack (Applied Bio-
systems) as well as the following primers and internal fluores-
cent probes: 
 
Foxp3
 
, 5
 
 
 
-GGCCCTTCTCCAGGACAGA-3
 
 
 
, 5
 
 
 
-
GCTGATCATGGCTGGGTTGT-3
 
 
 
, and 5
 
 
 
-FAM-ACT-
TCATGCATCAGCTCTCCACTGTGGAT-TAMRA-3
 
 
 
; and
 
 
 
-
 
actin
 
, 5
 
 
 
-AGAGGGAAATCGTGCGTGAC-3
 
 
 
, 5
 
 
 
-CAAT-
AGTGATGACCTGGCCGT-3
 
 
 
, and 5
 
 
 
-FAM-CACTGCCG-
CATCCTCTTCCTCCC-TAMRA-3
 
 
 
. For both 
 
Foxp3
 
 and
 
 
 
-actin
 
 mRNA quantitation, each sample was run in triplicate at
the same time as serial dilutions of a reference cDNA sample used
to generate a standard curve. Reported 
 
Foxp3
 
 mRNA levels are
normalized to the 
 
 
 
-actin
 
 mRNA levels of each sample.
 
Results
 
Instruction of Suppressor Commitment in Naive T Cells.
 
After initial hints that it might be possible to transform na-
ive T cells into CD4
 
 
 
25
 
 
 
 cells in vivo (2), a protocol was
designed to provide animals with a subimmunogenic regi-
men of peptide by implanting osmotic pumps that supplied
relatively low doses of peptide in saline at a constant rate
over a 2-wk time period. To exclude the possibility that
CD4
 
 
 
25
 
 
 
 cells were generated intrathymically or that
preexisting CD4
 
 
 
25
 
 
 
 suppressor T cells were simply ex-
panded, the initial experiments were performed in adult
Tx, RAG-2–deficient mice expressing a transgenic recep-
tor specific for peptide 107-119 from influenza hemagglu-
tinin (TCR-HA; reference 27; also referred to as TS1
mice; reference 18). When a daily dose of 10 
 
 
 
g of peptide
was applied, two concomitant events took place after 10 d
of continual infusion. CD4
 
 
 
25
 
 
 
 T cells that could be
stained with the clonotypic 6.5 receptor antibody appeared
with an increased frequency, whereas there was also an in-
Figure 1. Generation of CD25  Ag-specific suppressor T cells by
continuous peptide delivery for 14 d. (A) CD25 expression by
6.5 CD4  splenocytes of Tx TCR-HA,RAG-2 /  mice 14 d after
implantation of osmotic pumps delivering either PBS or 10  g of HA
peptide per day. (B) Percentages of 6.5  or 6.5 CD4  (top) and of
CD25 6.5 CD4  (bottom) T cells at various days of peptide delivery or
14 d after PBS infusion. (C) BrdU incorporation by splenocytes of either
Tx TCR-HA,RAG-2 /  mice within the 14 d of peptide osmotic pump
infusion or control TCR-HA,RAG-2 /  mice. (D) In vitro proliferation
of flow cytometry–purified CD4 6.5  T cells from untreated TCR-
HA,RAG-2 / (N) or from Tx TCR-HA,RAG-2 /  mice infused with
10  g/d of HA peptide for 14 d (P; black and dotted bars, respectively),
as well as CD25  (white bar) and CD25  (gray bar) subsets of 6.5 CD4 
cells from peptide-infused mice either cultured alone (unstriped bars)
or cocultured with naive 6.5 CD4  T cells from untreated TCR-
HA,RAG-2 /  mice (striped bars) in the presence of HA peptide-pulsed
x-irradiated BALB/c nude splenocytes. 
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crease in CD4
 
 
 
 cells that could no longer be stained with
the clonotypic reagent (Fig. 1, A and B). The latter may be
due to masking and/or internalization and degradation of
the idiotypic determinant. However, there was no detect-
able deletion as the absolute number of CD4
 
 
 
 T cells re-
mained constant over this time period (unpublished data).
To examine whether this form of peptide application
was accompanied by T cell activation and division as ob-
served after i.v. injection or oral administration of Ag (25),
mice were continuously infused with BrdU within the 14-d
period of peptide application, and, thereafter, BrdU in-
corporation was determined. Fig. 1 C shows that infusion
of peptide did not result in increased DNA synthesis by
CD4
 
 
 
 T cells when compared with CD4
 
 
 
 T cells from
control mice that were infused with BrdU in the absence
of peptide over the same time period. Also, no BrdU in-
corporation greater than the level of unstimulated controls
was detected after shorter BrdU pulses within the 14-d pe-
riod, excluding cell division and subsequent death of cells
(unpublished data). The absence of CD25 up-regulation on
CD4
 
 
 
 cells at early stages (Fig. 1 B, bottom) indicated that
the peptide infusion was not accompanied by T cell activa-
tion, as observed after immunogenic antigenic stimuli such
as injection of peptide in IFA that resulted in transient and
early CD25 up-regulation and proliferation, but not in the
generation of cells stably expressing CD25 (20).
Titration of the constantly supplied peptide dose indi-
cated that a daily dose of as little as 0.001  g was sufficient
to induce an increase in the frequency of CD4 25  cells
(Fig. 2 A) that, however, never exceeded 25% of all CD4 
6.5  cells. When CD25  and CD25  CD4  T cells from
pump-implanted mice were analyzed in vitro, the former
but not the latter were anergic in terms of Ag-induced pro-
liferation (Fig. 1 D) and could suppress the proliferative re-
sponse of naive T cells in the standard in vitro assay that is
often used to identify suppressor T cells (28), irrespective of
the inducing peptide dose (Fig. 2 C and not depicted).
Thus, in this assay, the unfractionated CD4 6.5  popula-
tion of cells was unresponsive to antigenic stimulation after
peptide infusion (i.e., it was composed of suppressor and
suppressed cells; Fig. 1 D).
In terms of some surface markers, CD4 25  cells gener-
ated with all tested doses of peptide resembled intrathymi-
cally generated suppressor cells with high levels of CTLA-4
and low levels of CD45RB, whereas the CD4 25  cells
with the same receptor were mostly CTLA-4 negative and
CD45RB high, but in contrast with naive cells, had down-
regulated the CD62L molecule (Fig. 2 B and not depicted).
Indistinguishable Phenotype of Natural and T Cell–derived
Suppressors.  To confirm that the CD4 25  cells were
generated de novo from naive CD4 25  cells rather than
representing a population of selected preexisting CD4 25 
cells, CD4 25  cells were sorted from TCR-HA,RAG-
2 /  mice and injected into thymus-deficient nu/nu mice
that were subsequently implanted with HA peptide–deliv-
ering osmotic pumps. The generated CD4 25  cells could
persist up to 10 wk after implantation of pumps (i.e., for 2
mo after termination of peptide delivery), while still being
committed to develop suppressive activity after antigenic
stimulation in vitro (Fig. 3, A and B). Similarly, CD4 25 
suppressor cells could persist for several months in Tx
TCR-HA,RAG-2 /  mice after termination of peptide
delivery (Fig. 3 B and not depicted). Thus, like natural sup-
pressors, regulatory T cells obtained by peptide–MHC liga-
tion of the TCR on naive T cells in vivo could persist for
long periods of time in the absence of their agonist peptide–
MHC complex in the form of CD25  T cells committed to
suppress after renewed stimulation by the TCR ligand.
When CD4 25  TCR-HA–expressing cells from
RAG-2   ,TCR-HA mice were transferred in low num-
bers to normal BALB/c mice such that they represented
Figure 2. Peptide dose–response relationship. (A) Percentages of
6.5 CD4  (left) and of CD25 6.5 CD4  (right) splenocytes in mice
given either PBS (10  g HA peptide/d) or 10 3, 10 1, 1, and 10  g HA
peptide/d for 14 d. (B) Expression of various markers by 6.5 CD4  T
cells of control mice (shaded histograms) and CD25  and CD25  subsets
of 6.5 CD4  cells (unshaded histograms) of mice 14 d after implantation
of osmotic pumps delivering 10 1  g HA peptide/d. (C) Suppressive
activity of CD25 CD4  TCR-HA transgenic T cells from mice infused
with various doses of HA peptide. Naive 6.5 CD4  T cells from untreated
TCR-HA,RAG-2 /  mice (N) were cultured alone or cocultured with
sorted CD25 6.5 CD4  T cells from Tx TCR-HA,RAG-2 /  mice (P,
CD25 ) given the indicated amount of peptide for 14 d in the presence of
HA peptide-pulsed x-irradiated BALB/c nude splenocytes. Data are ex-
pressed as cpm ([3H]TdR incorporation) of coculture experiments over that
of cultures of naive 6.5 CD4  T cells from control TCR-HA,RAG-2 / 
mice. One representative FACS® analysis of two independent ex-
periments is shown for each peptide dosage in (A and B). All mice
used in that experiment were age matched, Tx, and pump implanted
at the same time.In Vivo Induction of Ag-specific Dominant Tolerance in Naive T Cells 1404
0.2% of all CD4  cells,  20% of such cells became
CD4 25  cells 14 d after implantation of HA peptide–
delivering pumps, whereas they remained CD4 25  in un-
treated recipients (Fig. 3 C). Thus, the described procedure
is effective in inducing suppressor T cells from naive T cells
in a normal environment. Characterization of de novo
peptide-induced CD4 25  suppressor cells by quantitative
real-time PCR analysis of Foxp3 expression showed that, as
a rule, CD4 25  cells in various recipients and at various
time points after their induction expressed  10-fold higher
levels of this gene than CD4 25  cells within the same
mice as well as levels of Foxp3, which were similar to that
of control CD25 CD4  naturally generated suppressor T
cells (Fig. 3 D; reference 2). However, CD4 25  cells
clearly contained some significant levels of Foxp3  RNA
(Fig. 3 D), which could suggest that either they had initi-
ated, but not completed, a pathway to become suppressor
T cells or that they contained a minor fraction of CD25 
suppressor T cells too infrequent to suppress the prolifera-
tion of all CD25  cells. Thus, also by the criterion of
Figure 3. Long-term survival and Foxp3 expression by CD4 25  T cells generated from naive T cells. (A) Sorted CD25 negative 6.5 CD4  T cells
from Thy1.1 / ,TCR-HA,RAG-2 /  mice were transferred into BALB/c (Thy1.2 / ) nu/nu recipients implanted with osmotic pumps delivering 10
 g/d of HA peptide for 14 d. Expression of CD25 was monitored at various time points after implantation. (B) Suppressive in vitro activity of CD4 25 
TCR-HA–expressing cells from transferred and pump-implanted nu/nu as well as implanted Tx TCR-HA,RAG-2 /  mice at various time points after
delivery of peptide (10  g/d) for 14 d. (C) Generation of CD4 25  T cells from CD25 negative Thy1.1 / RAG-2   CD4 6.5  T cells transferred into
normal BALB/c mice that were implanted with peptide-delivery osmotic pumps (10  g/d). (D) cDNA was prepared from sorted CD25  6.5 CD4  and
CD25  6.5 CD4  subsets of either pump-implanted Tx TCR-HA,RAG-2    mice at day 14 and 16 wk, BALB/c nude mice adoptively transferred
with naive CD25 6.5 CD4  cells from Thy1.1   ,TCR-HA,RAG-2    mice 10 wk after implantation of osmotic pumps delivering peptide for 14 d,
naive 6.5 CD4  cells from TCR-HA,RAG-2    mice, or control suppressor CD25 6.5 CD4  cells of TCR-HA,Ig-HA mice. Foxp3 expression in
each of the aforementioned samples was determined by real-time RT-PCR and normalized to its  -actin mRNA levels. Data are representative of at least
two independent experiments.
Table I. Peptide Infusion Interferes with Diabetogenic Potential of T Cells
Recipient mouse Donor mouse
Transferred
cells (day 0) 
No. of
transferred cells
Diabetic
recipients
Days of
diabetes onseta
INS-HA nude RAG-2 / , TCR-HA  6.5 CD4  5   104  4/4   9.25    0.5
INS-HA nude implanted Tx RAG-2 / , TCR-HA 6.5 CD4   5    104  0/3b –
INS-HA nudec RAG-2 / , TCR-HA 6.5 CD4  5   104  0/4d –
aMean   SD.
bOne mouse showed normoglycemia for up to 33 wk of follow up, another one for up to 24 wk of follow up, and the last one for up to 15 wk
of follow up.
cINS-HA nude recipients were pump implanted  0.5 d before cell transfer.
dTwo recipients showed normoglycemia for up to 24 wk and two others for up to 15 wk after the examination was terminated.Apostolou and von Boehmer 1405
Foxp3 expression, CD4 25  suppressor T cells generated
de novo from mature naive T cells resembled intrathymi-
cally generated CD4 25  suppressor cells.
Induction of Ag-specific Dominant Tolerance In Vivo. It
was essential to demonstrate that the described procedure
did not only result in unresponsiveness of cocultured T
cells in vitro but also that the peripherally induced suppres-
sor cells could prevent the generation of effector T cells in
vivo. This was evaluated by injecting peptide-pulsed
splenic DCs into previously Tx and peptide-infused TCR-
HA,RAG-2 /  recipients (unpublished data) and by adop-
tive transfer of CD4  T cells from peptide-infused and
control mice into normal BALB/c mice that were subse-
quently challenged with Ag-pulsed splenic DCs. Fig. 4 A
shows that flow cytometry–purified naive CD4 6.5  as
well as CD25  and CD25 CD4  cells from peptide-
infused mice underwent seven to nine cell divisions after
antigenic challenge in vivo, but that the vast majority of
CD25  cells, when contained in the entire sorted CD4 
6.5  population (i.e., in the presence of CD4 25  suppres-
sive cells), exhibited much less proliferative potential. Thus,
expanding Ag-specific CD4 25  suppressor cells that ap-
peared to expand less well in the presence of CD4 25 
cells with the same antigenic specificity could very signifi-
cantly suppress the in vivo proliferation of the latter as re-
ported previously (2, 20). Furthermore, although 20–30%
of naive TCR-HA–expressing T cells transferred and anti-
genically challenged in normal BALB/c mice produced
IL-2 as well as IFN-  (irrespective of whether the entire
CD4  or only the recently activated CD4 25 Thy1.1  or
the CD4 25 Thy1.1  population was examined), this did
not occur when the same number of CD4  6.5  cells was
transferred from donors implanted previously with peptide-
delivering pumps (Fig. 4 B). Also, the CD4 25  suppressor
subset from peptide-infused mice failed to produce IL-2
and IFN-  (Fig. 4 B) as well as IL-4 and IL-10 (not de-
picted) after in vivo stimulation, which suggests that the
suppressive activity does not depend on the production of
these cytokines. Thus, by the criteria of both prolifera-
tion and cytokine production, the peptide delivery had
caused immunological tolerance in the entire CD4  T cell
population.
Finally, although naive CD4 6.5  cells from TCR-
HA,RAG-2 /  mice, when transferred into nu/nu mice
that express HA under control of INS-HA, caused diabetes
within 9 d, INS-HA–expressing mice receiving the same
number of CD4 6.5  cells from peptide-treated mice re-
mained diabetes free and exhibited normoglycemia for up
to 15, 24, or 33 wk when analysis was terminated (Table I).
It is worth noting that INS-HA recipient mice that re-
ceived peptide delivery by osmotic pumps 12 h before being
injected with naive CD4 6.5  T cells did not develop dia-
betes, suggesting that the described procedure might be
suited to interfere with ongoing immune responses (Table I).
Induction of Ag-specific Tolerance in Nontransgenic Mice.  It
was important to test whether tolerance could not only be
induced in cells expressing transgenic TCRs but also in
nonmanipulated CD4  cells by the described protocol.
Figure 4. Tolerance in CD4  cell populations from peptide-infused
mice. Sorted naive 6.5 CD4  T cells of control Thy1.1 / ,TCR-
HA,RAG-2 /  mice, sorted CD4  cells, and CD25 CD4  and
CD25 CD4  subsets of Ag-specific 6.5  cells of Tx Thy1.1 / ,TCR-
HA,RAG-2 /  mice treated with 10  g/ml of HA peptide for 14 d were
either CFSE labeled (A) or not labeled (B) and intrasplenically coinjected
with HA peptide-pulsed DCs into BALB/c mice. (A) 4.5 d later, spleno-
cytes of recipient mice were stained with CD4, CD25, and Thy1.1
mAbs. Dot plots show CD25 versus CFSE profiles of gated CD4 
Thy1.1  cells. (B) Splenocytes harvested at day 4.5 were stimulated in
vitro with HA peptide and stained with CD4, CD25, and Thy1.1 an-
tibodies as well as antibodies directed against cytokines. Staining for
intracellular IL-2 and IFN-  is shown for gated CD4 Thy1.1  cells as
well as their respective CD25  and CD25  subsets.
Figure 5. Ag-specific tolerance in peptide-infused nontransgenic
BALB/c mice. Control BALB/c mice and HA peptide-infused BALB/c
mice were immunized into the footpad with HA protein in IFA. Draining
LN cells of the latter mice as well as popliteal LN cells of unmanipulated
BALB/c mice were stimulated in vitro with either the whole HA protein
or the infused HA peptide. Data are mean   SD from triplicate wells and
are representative of at least two independent experiments.In Vivo Induction of Ag-specific Dominant Tolerance in Naive T Cells 1406
Therefore, BALB/c mice or HA peptide-infused BALB/c
mice (15 d after pump implant) were immunized into each
footpad with 1  g of highly immunogenic HA protein in
IFA. 13 d after immunization, draining LN cells as well as
mesenteric LN cells were collected and restimulated in
vitro with either the entire HA protein or the HA peptide.
Draining LN cells of immunized control mice proliferated
vigorously to both protein and peptide stimuli (Fig. 5),
whereas mesenteric LN cells from immunized mice and
LN cells of nonimmunized BALB/c mice did not (not de-
picted). HA peptide infusion of animals before immuniza-
tion resulted in the complete suppression of the in vitro re-
call response of draining LN cells to both in vitro stimuli
(Fig. 5). Thus, the described peptide infusion is suited to
induce tolerance to the entire protein from which the pep-
tide is derived in normal mice.
Discussion
The described experiments indicate that a relatively sim-
ple procedure of delivering peptide for a prolonged time
period in subimmunogenic forms is suited to induce de
novo CD4 25  suppressor T cells from naive T cells in pe-
ripheral lymphoid organs in the absence of a functioning
thymus as well as in the absence of a developing immune
response. By all investigated criteria (i.e., surface pheno-
type, long-term stability in the absence of the inducing
TCR ligand, Foxp3 expression, Ag-induced expansion in
vivo, and suppressive activity in vitro and in vivo as well as
cytokine production), the induced suppressor T cells are
indistinguishable from intrathymically generated CD4 25 
T cells that were shown to have an essential role in pre-
venting autoimmunity under physiological conditions.
The described experiments are akin to studies conducted
by i.v. injection of soluble proteins that were described de-
cades ago and that became known as “low zone tolerance”
experiments (29, 30). It is well possible that, also under
those condition, tolerance was due to the induction of sup-
pressor cells as might also be the case in desensitization at-
tempts that have the goal to reduce allergic reactions by ap-
plying relevant protein derivatives.
In vivo and ex vivo inductions of suppressor T cells
by chronic antigenic stimulation was achieved by several
groups (7, 24, 31–35), but gave rise to regulatory T cell
subsets that appear to be distinct from natural CD25  sup-
pressor cells. Some in vivo protocols made use of chemicals
that affect the entire immune system and, thus, may not be
ideally suited to induce Ag-specific unresponsiveness (36).
Ex vivo generation of Ag-specific CD25  suppressor T
cells with IL-2 and TGF-  that resemble naturally occur-
ring suppressor T cells has been reported previously (36,
37), but little is known about the long-term survival of
these cells in vivo in the absence of Ag. In one particular
setting of suppressor T cell induction in vivo, it was found
that CD4 25  anergic cells could accumulate after i.v. or
oral administration of Ag, but Foxp3 expression was not
analyzed (25). Whether this resulted from de novo genera-
tion of suppressor cells or their selection was not entirely
clear. Also, this particular protocol appeared to induce a
transient immune response that was not observed after pep-
tide infusion.
The mechanism by which the peripheral differentia-
tion of naive T cells into CD25  Ag-specific suppressor
cells that resemble by all criteria natural suppressor cells
as reported in the present work remains to be defined. It
is possible that this process could be initiated by interac-
tions with HA peptide–presenting nonactivated DCs
such as epidermal Langerhans cells, which are at the site
of osmotic pump implant, can endocytose efficiently,
and are endowed with trafficking capacity to secondary
lymphoid tissues where they can induce tolerance in the
steady state (38, 39). Thus far, it has been demonstrated
that Ag presentation by nonactivated DCs can result in
recessive tolerance (40, 41), but it is possible that low
doses of peptide presented over relatively long time pe-
riods (10 d) on nonactivated DCs represents a natural
way of inducing active immunosuppression by which
the immune system prevents immune responses to self
components that do not induce tolerance in the thymus.
Such a scenario may also lead to the suppression of anti-
tumor responses when tumor-specific peptides are pre-
sented in subimmunogenic form. At present, it is not
entirely clear how the immune system can evade this
suppression, but strong activation of APCs may be one
mechanism (42).
The fact that naive CD25  T cells can be instructed
in vivo, as reported here, or in vitro (13, 26) to become
Foxp3-expressing CD25  suppressor cells raises the ques-
tion of whether naturally occurring Foxp3-expressing
CD25  suppressor T cells that develop in the thymus con-
stitute a lineage distinct from that of their peripherally in-
duced counterparts, or whether such cells reflect the ex-
istence of a single Foxp3-expressing naturally occurring
CD25  suppressor lineage that can develop under nonin-
flammatory steady state conditions in primary as well as
secondary lymphoid tissues.
It needs to be tested whether the procedure described
here will be suited to induce prospective tolerance to a
large variety of Ags, including transplantation Ags. By
means of single peptides, efficient suppression could be
achieved because suppressor cells cannot only suppress re-
sponses of T cells with the same Ag specificity but also
responses of neighboring T cells that happen to interact
with other ligands in the vicinity of suppressor T cells (by-
stander suppression). Thus, it will be of interest to monitor
whether, eventually, the in vivo induction of Ag-specific
suppressor cells by the described procedure will make gen-
eral immune suppression the therapy of the past.
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